Stockscreener 앱 받기
9.55
1.49%
0.14
시장 영업 전:
9.79
0.24
+2.51%
전일 마감가:
$9.41
열려 있는:
$9.27
하루 거래량:
774.92K
Relative Volume:
0.96
시가총액:
$633.76M
수익:
$46.02M
순이익/손실:
$-70.80M
주가수익비율:
-5.2473
EPS:
-1.82
순현금흐름:
$-1.61M
1주 성능:
+4.03%
1개월 성능:
+31.91%
6개월 성능:
+28.19%
1년 성능:
+14.92%
1일 변동 폭
$8.955
$9.595
1주일 범위
$8.88
$10.77
52주 변동 폭
$3.91
$13.98
Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile
명칭
Eyepoint Pharmaceuticals Inc
전화
617-926-5000
주소
480 PLEASANT STREET, WATERTOWN, MA
EYPT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Pharmaceuticals Inc
|
9.55 | 633.76M | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-07 | 개시 | Citigroup | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-28 | 개시 | Jefferies | Buy |
| 2024-01-22 | 개시 | JP Morgan | Overweight |
| 2023-11-02 | 개시 | Mizuho | Buy |
| 2023-04-21 | 개시 | Robert W. Baird | Outperform |
| 2022-07-07 | 개시 | Chardan Capital Markets | Buy |
| 2021-03-01 | 개시 | Cowen | Outperform |
| 2021-01-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-04-06 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | 재개 | Laidlaw | Buy |
| 2019-09-12 | 개시 | Guggenheim | Buy |
모두보기
Eyepoint Pharmaceuticals Inc 주식(EYPT)의 최신 뉴스
Forecasting The Future: 4 Analyst Projections For EyePoint Pharmaceuticals - Benzinga
RBC Capital Initiates Coverage on EyePoint Pharmaceuticals (EYPT - GuruFocus
EyePoint Pharmaceuticals (EYPT) Poised for Success with Positive Outlook | EYPT Stock News - GuruFocus
RBC Capital Initiates EyePoint Pharmaceuticals at Outperform With $28 Price Target - MarketScreener
After Leaping 47% EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Are Not Flying Under The Radar - simplywall.st
EyePoint (EYPT) Grants Stock Options to New Employees as Inducement | EYPT Stock News - GuruFocus
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 563 - GuruFocus
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - EyePoint Pharmaceuticals
EyePoint Awards 12,500 Shares in Stock Options to Three New Hires at $9.03 Per Share - Stock Titan
(EYPT) Trading Report - news.stocktradersdaily.com
EyePoint Stock: Retaining My 'Risky Buy' CallPivotal Data Due Early 2026 (NASDAQ:EYPT) - Seeking Alpha
Cantor Fitzgerald Weighs in on EYPT FY2026 Earnings - Defense World
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Recommendation of “Buy” from Analysts - Defense World
EyePoint at Goldman Sachs Healthcare Conference: Sustained-Release Vision By Investing.com - Investing.com Canada
Breakout Momentum Plays You May Not Know About - Investing.com
Squarepoint Ops LLC Has $302,000 Stock Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
Ameriprise Financial Inc. Grows Stock Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
Nuveen Asset Management LLC Raises Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
ProShare Advisors LLC Buys 8,981 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
(EYPT) Investment Report - news.stocktradersdaily.com
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $276,000 Stock Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
Eyepoint projects DURAVYU Phase 3 enrollment completion by H2 2025 amid strong clinical trial momentum - MSN
Millennium Management LLC Buys New Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
EyePoint advances with Duravyu Phase III trial - Yahoo
H.C. Wainwright maintains Buy on EyePoint with $22 target - Investing.com India
H.C. Wainwright maintains Buy on EyePoint with $22 target By Investing.com - Investing.com Nigeria
EyePoint Pharmaceuticals (NASDAQ:EYPT) shareholders are up 29% this past week, but still in the red over the last year - simplywall.st
EyePoint Pharmaceuticals’ (EYPT) Buy Rating Reaffirmed at HC Wainwright - Defense World
Biggest Companies on Nasdaq EyePoint Pharmaceuticals Insights by Kalkine - Kalkine Media
Analyst Expectations For EyePoint Pharmaceuticals's Future - Benzinga
EyePoint Pharmaceuticals (EYPT) Reiterates Buy Rating with $22 P - GuruFocus
EyePoint Pharmaceuticals (EYPT) Reiterates Buy Rating with $22 Price Target | EYPT Stock News - GuruFocus
Bank of America Corp DE Acquires 145,065 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
EyePoint Announces Participation at Upcoming Investor Conferences - The Manila Times
EyePoint Secures Triple Conference Spotlight: Goldman Sachs, Jefferies, and Guggenheim Healthcare Events - Stock Titan
EYPTEyepoint Pharmac Latest Stock News & Market Updates - Stock Titan
EyePoint at Stifel Forum: Strategic Advances in Ophthalmology By Investing.com - Investing.com Canada
JPMorgan maintains EyePoint stock Overweight with $26 target - Investing.com India
JPMorgan maintains EyePoint stock Overweight with $26 target By Investing.com - Investing.com UK
Eyepoint Completes Enrollment In Pivotal Phase 3 Lugano Trial Of Duravy For Treatment Of Wet Age-Related Macular Degeneration - marketscreener.com
EyePoint (EYPT) Surpasses Enrollment Goal in Key Phase 3 Trial | - GuruFocus
EyePoint Completes Enrollment for DURAVYU Phase 3 Trial - TipRanks
EyePoint Pharmaceuticals Reports Rapid Enrollment Progress in Phase 3 LUGANO Trial of DURAVYU™ for Wet AMD Treatment - Nasdaq
EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration - The Manila Times
Clinical Trial Milestone: EyePoint's Revolutionary 6-Month Eye Treatment Completes Phase 3 Enrollment - Stock Titan
EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors - The Globe and Mail
Deutsche Bank AG Has $1.59 Million Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
BNP Paribas Financial Markets Purchases New Shares in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
(EYPT) Trading Signals - news.stocktradersdaily.com
Northern Trust Corp Has $4.79 Million Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
Insider Buying: Karen Zaderej Acquires Additional Shares of EyeP - GuruFocus
Eyepoint Pharmaceuticals Inc (EYPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Eyepoint Pharmaceuticals Inc 주식 (EYPT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Zaderej Karen L. | Director |
May 19 '25 |
Buy |
5.99 |
5,000 |
29,950 |
36,500 |
| Zaderej Karen L. | Director |
May 16 '25 |
Buy |
5.81 |
5,000 |
29,050 |
31,500 |
| Zaderej Karen L. | Director |
May 15 '25 |
Buy |
5.47 |
5,000 |
27,350 |
26,500 |
| Zaderej Karen L. | Director |
May 14 '25 |
Buy |
5.42 |
5,000 |
27,100 |
21,500 |
| Elston George | Chief Financial Officer |
Feb 09 '25 |
Option Exercise |
0.00 |
5,834 |
0 |
75,550 |
| Lurker Nancy | Director |
Feb 09 '25 |
Option Exercise |
0.00 |
20,000 |
0 |
205,436 |
| Duker Jay S. | President and CEO |
Feb 09 '25 |
Option Exercise |
0.00 |
7,000 |
0 |
79,706 |
| Elston George | Chief Financial Officer |
Jan 06 '25 |
Option Exercise |
0.00 |
15,285 |
0 |
73,374 |
| Elston George | Chief Financial Officer |
Jan 05 '25 |
Option Exercise |
0.00 |
15,000 |
0 |
63,356 |
| Lurker Nancy | Director |
Jan 06 '25 |
Option Exercise |
0.00 |
75,134 |
0 |
185,436 |
0.39%
0.42%
자본화:
|
볼륨(24시간):